BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $120 from $112 and keeps an Outperform rating on the shares. The myelofibrosis, MF, anemia key opinion leader event gives a comprehensive look at the treatment landscape and how Disc Medicine remains early but differentiated, the analyst tells investors in a research note. Following the event and the firm’s recent Phase 3 INDEPENDENCE luspaterecpt data preview, BMO is more encouraged by DISC-0974’s value and its positioning in MF anemia as DISC-0974 has shown potential to be used as a monotherapy, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman
- Promising Outlook for Disc Medicine’s DISC-0974 in Anemia Treatment Justifies Buy Rating
- Disc Medicine Reports Strong Q1 2025 Progress
- Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements
- Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue